Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Disulfiram (HB1119)
Description:Reversibly stimulates SERCA Ca2+-ATPase. V-ATPase inhibitor.
Purity:>97%
FK 506 (HB0289)
Description:Potent calcineurin phosphatase 2B inhibitor. Enhances osteoblastic differentiation in mesenchymal cells.
Purity:>99%
FTY720 hydrochloride (HB3899)
Description:Sphingosine 1-phosphate (S1P) receptor (S1P1, S1P3, S1P4, and S1P5) modulator
Purity:>98%
Haloperidol hydrochloride (HB1842)
Description:Dopamine receptor antagonist with partial D2-like selectivity
Purity:>99%
Imatinib mesylate (HB1943)
Description:Tyrosine kinase inhibitor that targets BCR‑ABL, c‑KIT, and PDGFR kinases
Purity:>98%